3D Medicines, Inc. (HK:1244)
:1244
Want to see HK:1244 full AI Analyst Report?
1244 Stock Chart & Stats
HK$6.14
-HK$0.10(-2.80%)
At close: 4:00 PM EST
HK$6.14
-HK$0.10(-2.80%)
Day’s Range― - ―
52-Week RangeHK$2.51 - HK$10.02
Previous CloseN/A
Volume120.00K
Average Volume (3M)393.13K
Market Cap
HK$759.04M
Enterprise ValueHK$605.77M
Total Cash (Recent Filing)HK$438.10M
Total Debt (Recent Filing)HK$152.85M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding258,177,000
10 Day Avg. Volume535,000
30 Day Avg. Volume393,126
Financial Highlights & Ratios
PEG Ratio1.66
Price to Book (P/B)1.97
Price to Sales (P/S)3.30
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~92% gross margin is a durable fundamental strength for a biotech commercializing therapies: it indicates strong product economics and pricing power. High gross margins give the company structural capacity to fund R&D and commercialization even if operating expenses remain elevated, supporting long-term viability if revenues stabilize.
Narrowing LossesThe material reduction in losses versus prior years signals improving operating discipline or a better product mix. This trend, if sustained, reduces future capital needs and indicates management is moving the business toward break-even, a durable positive for financing flexibility and investor confidence over months.
Manageable LeverageLow and declining leverage provides structural financial flexibility for a clinical-stage/commercial biotech. A modest debt load reduces near-term refinancing risk and preserves capacity to fund trials, launches, or strategic partnerships without being overly constrained by interest or covenants.
Bears Say
Persistent Negative Cash FlowSustained negative OCF and FCF indicate the company is structurally cash-consuming, raising reliance on external financing or dilution. Continued cash burn constrains the pace of clinical programs and commercialization investments and increases execution risk if access to capital tightens over the coming months.
Revenue ContractionA multi-year top-line decline undermines operating leverage and the company’s ability to convert high gross margins into positive operating profit. Structural revenue weakness raises questions about market adoption, pricing or competitive pressures that will materially affect the path to sustainable profitability.
Equity Erosion & Negative ROEPersistent losses are eroding shareholders' equity and produce a deeply negative ROE, weakening balance-sheet resilience. Over time this increases the probability of dilutive capital raises or restructuring, which can impair long-term shareholder value and limit strategic optionality.
3D Medicines, Inc. News
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$2.51 and its highest was HK$10.02 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$759.04M.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Aug 28, 2026 which is in 71 days.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Mar 31, 2026. The company reported -HK$0.392 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.392.
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.392 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.866%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3D Medicines, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.03%
12-Months-Change
Fundamentals
Return on Equity
-27.04%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
3D Medicines, Inc.
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Technical Analysis
Alphamab Oncology
―
JW (Cayman) Therapeutics Co. Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---